Viewing Study NCT04332692


Ignite Creation Date: 2025-12-24 @ 3:48 PM
Ignite Modification Date: 2025-12-24 @ 3:48 PM
Study NCT ID: NCT04332692
Status: RECRUITING
Last Update Posted: 2023-06-05
First Post: 2020-03-12
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: Acute Heart Failure - COngestion Discharge Evaluation
Sponsor: Central Hospital, Nancy, France
Organization:

Study Overview

Official Title: Acute Heart Failure - COngestion Discharge Evaluation. Évaluation de la Congestion à la Sortie d'Hospitalisation Pour Insuffisance Cardiaque aiguë.
Status: RECRUITING
Status Verified Date: 2023-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: AHF-CODE
Brief Summary: Acute heart failure (AHF) is a major public health problem, associated with a 40% risk of death or re-hospitalisation at 3 months. This risk is significantly increased by insufficient decongestion at the end of hospitalisation for AHF assessed by a standardised clinical score, a natriuretic peptide dosage or by cardiac and pulmonary ultrasound .

Adapting treatment according to lung congestion assessed by implantable devices (not reimbursed in France) improves the prognosis. However, due to the lack of a standardised congestion assessment, therapeutic adaptation in acute heart failure is currently empirical. The best multimodality approach to congestion evaluation is uncertain.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: